In April 2025 Pfizer discontinued development of the oral GLP-1 receptor agonist danuglipron for chronic weight management after late-stage trials revealed a drug-induced liver injury (DILI) signal with elevated liver enzymes. The decision ended a years-long effort to field a small-molecule GLP-1 pill and came after an earlier once-daily formulation had already been shelved in 2023 for the same reason. The exit narrows the oral GLP-1 race to Lilly's orforglipron and Novo Nordisk's oral semaglutide, and it is a cautionary safety case for the broader peptide-therapeutics field on hepatotoxicity surveillance.